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INTRODUCTION
Mucopolysaccharidosis type I (MPS I) is a rare autosomal 
recessive disease caused by a deficiency of α-l-iduronidase, 
an enzyme required for the degradation of the glycosamino-
glycans dermatan and heparan sulfate. The estimated incidence 
of MPS I is 1 in every 100,000 live births. Due to the chronic 
and progressive accumulation of glycosaminoglycans in the 
lysosomes of cells throughout the body, patients affected by this 
devastating disease experience multiorgan dysfunction leading 
to considerable morbidity in most patients, and early mortality 
in those most severely affected.1
Like most other metabolic inherited diseases, MPS I dis-
plays significant variability in its presentation and course. 
This may be due to differences among patients in the sever-
ity of the underlying mutation(s) and consequent degree of 
residual enzyme activity; however, other factors may also 
contribute to the well-known phenotypic heterogeneity.2 
Historically, MPS I has been classified into three syndromes—
Hurler, Hurler–Scheie, and Scheie—though it is now widely 
accepted that overlap in symptomatology exists among these 
subtypes.1 Hurler syndrome, the most severe form of MPS I, 
typically involves significant developmental delay and cogni-
tive decline, along with characteristic coarse facial features, 
joint stiffness and contractures, short stature, and respira-
tory, cardiac, and hepatic disease. Symptoms emerge shortly 
after birth and progress rapidly, such that most patients with 
Hurler syndrome die within the first decade of life. At the 
other end of the MPS I disease spectrum, Scheie syndrome 
involves later onset of typically milder symptoms and a slower 
disease progression. While patients with the Scheie pheno-
type usually develop significant disease-related morbidity, 
they show normal intelligence and survive into adulthood. 
Hurler–Scheie syndrome represents an intermediate pheno-
type that is characterized by mild or no cognitive impairment 
but includes somatic symptoms that reduce life expectancy 
into the second or third decade of life. Delineation of the dif-
ferent MPS I phenotypes can be challenging and is largely 
driven by consideration of the age of symptom onset and rate 
of disease progression as well as a patient’s genotype.3
Historically, treatment of MPS I was restricted to palliative 
care and symptom-based interventions, including surgery 
(e.g., adenotonsillectomy, hernia repair, ventriculoperitoneal 
shunt, cardiac valve replacement, carpal tunnel release, and 
spinal decompression); physical, occupational, and speech 
therapies; respiratory support; hearing aids; and medications 
for pain and gastrointestinal disturbances. Since 1981, hemato-
poietic stem cell transplantation (HSCT) has been used to treat 
MPS I. When successful, it is a one-time procedure that can 
prolong survival, preserve cognitive function, and reduce some 
somatic features of the disease.4,5 However, due to its significant 
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Purpose: In this study, we aimed to describe the natural history of 
mucopolysaccharidosis I.
Methods: Data from 1,046 patients who enrolled in the MPS I Reg-
istry as of August 2013 were available for descriptive analysis. Only 
data from untreated patients and data prior to treatment for patients 
who received treatment were considered. Age at symptom onset, 
diagnosis, and treatment initiation were examined by geographic 
region and phenotype (from most to least severe: Hurler, Hurler–
Scheie, and Scheie). For each symptom, frequency and age at onset 
were examined.
Results: Natural history data were available for 987 patients. Most 
patients were from Europe (45.5%), followed by North America 
(34.8%), Latin America (17.3%), and Asia Pacific (2.4%). Phenotype 
distribution was 60.9% for Hurler, 23.0% for Hurler–Scheie, and 
12.9% for Scheie (3.2% undetermined) syndromes. Median age at 
symptom onset for Hurler, Hurler–Scheie, and Scheie syndromes was 
6 months, 1.5 years, and 5.3 years, respectively; median age at treat-
ment initiation was 1.5 years, 8.0 years, and 16.9 years, respectively. 
Coarse facial features and corneal clouding were among the most 
common symptoms in all three phenotypes.
Conclusion: A delay between symptom onset and treatment 
exists, especially in patients with attenuated mucopolysaccharido-
sis I. A better understanding of disease manifestations may help 
facilitate prompt diagnosis and treatment and improve patient out-
comes.
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morbidity, HSCT is reserved for patients with the most severe 
form of MPS I, Hurler syndrome. HSCT is typically recom-
mended for patients under 2 years of age with normal cognition 
(intelligence quotient >70) because early intervention increases 
the likelihood of maintaining cognitive abilities. For patients 
with Hurler–Scheie and Scheie syndromes, enzyme replace-
ment therapy (ERT) with laronidase (recombinant human 
α-l-iduronidase; Aldurazyme) is the primary treatment 
option.6–10 Laronidase is administered weekly via intravenous 
infusion and is a lifelong therapy.
The success of both HSCT and ERT may depend on early ini-
tiation of treatment. Developmental outcomes are better when 
transplantation is performed before 24 months of age,11 and 
laronidase may also be more beneficial when started early in 
life, based on the suggestion from two case reports on siblings 
with Hurler–Scheie syndrome.12,13 Unfortunately, early diagno-
sis (and hence early initiation of treatment) is limited by several 
factors, including the rarity of the disease, the wide variability 
in clinical presentation and disease course, and the nonspecific 
nature of some of the early manifestations of the disease. As 
is true of other rare genetic diseases, MPS I awareness among 
physicians is also hampered by a general lack of familiarity with 
its symptoms and course.
With the advent of several potentially lifesaving therapies, 
the need for better disease recognition and early diagnosis is 
heightened. The MPS I Registry (ClinicalTrials.gov identifier: 
NCT00144794) is a global, observational disease database 
established in 2003 by Genzyme/BioMarin and is maintained 
by Genzyme, a Sanofi company.12 The collection of data in the 
Registry is aimed at facilitating characterization of the course 
of disease and tracking clinical outcomes in patients with MPS 
I. In addition, participating health-care professionals are pro-
vided access to aggregate data on MPS I and can query the 
database for specific information to facilitate the care of their 
patients with MPS I. Analyses of data from the Registry have 
provided insights about disease burden, genotype–phenotype 
correlations, frequency and risks of surgical procedures, and 
changing treatment trends in MPS I patients.13–15 The intent 
of this analysis is to use data from the Registry to describe the 
natural history of MPS I by phenotype and across regions in an 
effort to improve the recognition and prompt diagnosis of this 
potentially fatal, but treatable, disease.
MATeRIALS AND MeTHODS
The global MPS I Registry was initiated in April 2003 as part 
of an effort to help health-care professionals involved in the 
diagnosis and treatment of MPS I better understand the disease 
and its management and to help create MPS I disease treatment 
monitoring guidelines. All data provided for this analysis were 
obtained as of August 2013. Patient participation in the MPS I 
Registry is voluntary. Each independent site is responsible for 
obtaining a patient’s informed consent for submitting his/her 
health information to the Registry and for using and disclosing 
this information in subsequent aggregate analyses, such as jour-
nal articles, annual reports, educational materials, and public 
health reports. Historically, each independent site has been 
responsible for determining whether site-specific institutional 
review board or ethics committee review is required for partici-
pation in the Registry in accordance with institutional policies 
and local laws and regulations. Since December 2012, the MPS 
I Registry protocol has required sites to submit to and receive 
approval from an institutional review board or ethics commit-
tee. All patient data are anonymized and entered by participat-
ing sites in accordance with applicable privacy regulations. At 
enrollment, detailed medical histories and baseline data are col-
lected and physicians are encouraged to follow a recommended 
schedule of clinical assessments and regularly report the results 
of their assessments.12
This report is based on Registry data as of August 2013, at 
which time information was available for 1,046 patients. The 
Registry includes comprehensive information for treated as 
well as untreated patients; for the treated patients, data are avail-
able from the periods prior to, during, and/or subsequent to 
treatment. Therefore, a definition of the natural history period 
and the following patient inclusion criteria were used to select 
data for the analyses presented here: (i) Known ERT status, 
(ii) For patients receiving ERT, known date of first infusion, 
(iii) Known HSCT status, and (iv) For patients who had received 
HSCT, known date of transplant.
From the initial cohort of 1,046 patients, 987 patients met 
the inclusion criteria. For patients who had never been treated, 
the natural history period was defined as the time from birth 
to the last follow-up recorded in the Registry. Among patients 
who had been treated with ERT, HSCT, or both, the natural his-
tory period was defined as the time from birth to first treatment 
(either ERT or HSCT).
Ages at first symptom, diagnosis, and treatment initiation 
(where applicable) were evaluated by region and MPS I pheno-
type. Symptom prevalence and age of onset of symptoms relat-
ing to general appearance and neurologic, cardiac, respiratory, 
gastrointestinal, and musculoskeletal status were evaluated by 
phenotype. Only the symptoms observed during the predefined 
natural history period were considered. Given that not all 
patients had data reported for every symptom during the natu-
ral history period, the assumption was made that symptoms 
not explicitly reported were not present, and frequencies were 
calculated as the number of patients with the symptom present 
divided by all patients in each region and/or phenotype. This 
assumption means that the reported frequencies may underesti-
mate the true frequency for each symptom. Descriptive statistics 
were computed for age of onset of each symptom (as indicated 
by the earliest age each symptom was reported) among patients 
who experienced the symptom. For those patients with the 
same symptom reported multiple times, the earliest age was 
used, corresponding to “onset” or “age first reported.” 
ReSULTS
Global occurrence of MPS I phenotypes
A total of 987 MPS I patients with evaluable natural history 
information were enrolled in the Registry as of August 2013 
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(Table 1). The largest proportion of patients was from Europe 
(45.5%), with the next largest from North America (34.8%), fol-
lowed by Latin America (17.3%) and Asia Pacific (2.4%).
The overall phenotypic distribution was 601 (60.9%) for 
Hurler, 227 (23.0%) for Hurler–Scheie, and 127 (12.9%) for 
Scheie. Another 32 (3.2%) patients met the criteria for inclusion 
in this analysis, but their phenotypes were not reported in the 
Registry and were therefore considered undetermined or miss-
ing. Of note, North America (71.4%) and Europe (61.5%) had 
higher proportions of patients with the severe Hurler phenotype 
than Latin America (42.7%) or the Asia Pacific region (29.2%).
Chronology of symptom onset, diagnosis, and treatment 
by region
Median ages at symptom onset, MPS I diagnosis, and first treat-
ment (ERT or HSCT, if applicable) are presented by region and 
phenotype in Figure 1. Across all regions, patients with Hurler 
syndrome, the most severe phenotype, were diagnosed and 
treated earliest, as expected. The median age at symptom onset 
for these patients was 6 months, and diagnosis and treatment 
initiation followed quickly thereafter, at median ages of 12 and 
18 months, respectively. Patients with Hurler–Scheie and Scheie 
syndromes, which have the more attenuated presentations, typ-
ically experienced initial symptoms sometime after infancy and 
exhibited a 2- to 4-year gap between onset of symptoms and 
diagnosis, respectively, and a 4- to 8-year gap between diagno-
sis and treatment initiation, respectively.
Analyses of age of symptom onset, diagnosis, and treatment 
initiation based on phenotype and geographic region generally 
mirrored the results in the overall Registry population, with a 
few notable exceptions. In North America, treatment initiation 
for patients with Scheie syndrome was earlier than in the other 
regions. The median age for treatment initiation for patients 
diagnosed with Scheie syndrome in North America was 11.7 
years, whereas in Europe and Latin America it was 16.9 and 17.7 
years, respectively. The Asia Pacific region had an even higher 
median age of 31.5 years for treatment initiation. The median 
age of treatment initiation in patients with Hurler–Scheie was 
also higher in the Asia Pacific region (23.8 years) compared 
with the overall Registry population (8 years). Another nota-
ble finding was the rate of patients with an undetermined or 
missing phenotype in Latin America (11.1%), which was much 
higher compared with the other regions. The median ages of 
symptom onset, diagnosis, and treatment initiation for patients 
in Latin America with an undetermined phenotype were 0.7, 
1.3, and 3.3 years, respectively, which is highly comparable to 
the median ages for patients in Latin America with the Hurler 
phenotype (0.7, 1.7, and 3.6 years, respectively), suggesting that 
some portion of the patients with undetermined phenotypes 
may, in fact, have Hurler syndrome.
Natural history of MPS I by phenotype
Symptom frequency by phenotype. Coarse facial features 
were the most predominant characteristic of all functional 
and anatomic abnormalities for both the Hurler and the 
Hurler–Scheie phenotypes, occurring in 86.4 and 72.7% of 
these patients, respectively. The symptoms occurring in at least 
25% of patients are summarized by phenotype in Figure 2, 
and all symptoms, including those occurring in less than 25% 
of patients, are summarized by phenotype in Supplementary 
Table S1 online. Among patients with the Scheie phenotype, 
48.0% presented with coarse facial features. Corneal clouding 
was noted in all three phenotypes at approximately the same 
rate: 70.9, 68.3, and 70.1% for Hurler, Hurler–Scheie, and 
Scheie, respectively.
Hepatomegaly was present in the majority of patients with 
Hurler (70.0%) and Hurler–Scheie (66.5%) phenotypes and in 
approximately half (48.0%) of those with the Scheie phenotype. 
Similarly, splenomegaly was present in 50.9% of patients with 
Hurler syndrome and 47.1% of patients with Hurler–Scheie 
syndrome but in only 27.6% of those with the Scheie pheno-
type. The incidences of hernias were more evenly distributed 
among the phenotypic groups, with 58.9% in Hurler, 59.9% in 
Hurler–Scheie, and 53.5% in Scheie patients.
In terms of musculoskeletal abnormalities, kyphosis/gib-
bus was the only abnormality present in the majority (70.0%) 
of patients with Hurler phenotype, and it was reported much 
less frequently in patients with Hurler–Scheie (33.5%) and 
Scheie (21.3%) phenotypes. Conversely, joint contractures 
and carpal tunnel syndrome were present in the majority of 
Scheie patients (69.3 and 51.2%, respectively) but were less 
common in Hurler–Scheie patients (57.3 and 27.8%, respec-
tively) and even less frequent in Hurler patients (37.9 and 
7.8%, respectively).
Cardiac valve abnormalities were observed in 67.7% of 
Scheie patients, 59.0% of Hurler–Scheie patients, and 48.9% of 







n (%) Undetermined,a n (%)
Total,b 
n (%)
All regions 601 (60.9) 227 (23.0) 127 (12.9) 32 (3.2) 987
Asia Pacific 7 (29.2) 5 (20.8) 12 (50.0) 0 24 (2.4)
Europe 276 (61.5) 102 (22.7) 63 (14.0) 8 (1.8) 449 (45.5)
Latin America 73 (42.7) 57 (33.3) 22 (12.9) 19 (11.1) 171 (17.3)
North America 245 (71.4) 63 (18.4) 30 (8.7) 5 (1.5) 343 (34.8)
MPS I, mucopolysaccharidosis type I.
aPercentages are based on the number of patients in each region enrolled in the Registry who met the criteria for inclusion in this analysis as of 2 August 2013.
bPercentages are based on the number of patients in all regions enrolled in the Registry who met the criteria for inclusion in this analysis as of 2 August 2013.
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Hurler patients. Airway-related symptoms, such as sleep dis-
turbances/snoring were observed in 51.6% of Hurler patients, 
48.9% of Hurler–Scheie patients, and 26.8% of Scheie patients. 
Cognitive impairment was observed in 46.4, 31.3, and 9.4% of 
patients with Hurler, Hurler–Scheie, and Scheie phenotypes, 
respectively.
Age of symptom onset by phenotype
As expected, first symptoms appeared earlier (within the first 2 
years of life) in patients with the Hurler phenotype; whereas, in 
patients with the Hurler–Scheie and Scheie phenotypes, com-
monly occurring symptoms were first observed between 3 and 
7, and 5 and 13 years of age, respectively. The median ages of 
Figure 1 Median age of onset of symptoms, diagnosis, and treatment by phenotype. (a) All regions, (b) Asia Pacific, (c) Europe, (d) Latin America, 
and (e) North America. Median age in years (left axis) calculated on the basis of patients within each phenotype for whom age of symptom onset, diagnosis, 
or treatment was recorded. The median age in years is noted above each column. The number of patients, n, is noted below each column. In b, the median 
age of symptom onset is higher than the median age of diagnosis for the five Hurler–Scheie patients, even though all five had an age of symptom onset less 
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onset of symptoms occurring in at least 25% of patients are pre-
sented by phenotype in Figure 2, and the median ages of onset 
of all symptoms, including those occurring in less than 25% 
of patients, are summarized by phenotype in Supplementary 
Table S2 online.
Across all phenotypes, hernias were the earliest reported 
symptom, which was noted at median ages of 0.8, 3.2, and 
4.6 years of age in Hurler, Hurler–Scheie, and Scheie patients, 
respectively. Coarse facial features, the most prevalent symp-
tom in patients with Hurler and Hurler–Scheie phenotypes, 
were also an early finding, with a median age at onset of 0.9 
years in Hurler patients and 3.4 and 8.7 years in patients with 
Hurler–Scheie and Scheie phenotypes, respectively. Corneal 
clouding, the most prevalent symptom in patients with the 
Scheie phenotype, was first noted at a median age of 10.5 years 
in that subset of patients.
Among patients with the Hurler phenotype, kyphosis/gib-
bus had a median age at onset of 1.0 year (Figure 2a), and dys-
ostosis multiplex, corneal clouding, and hepatomegaly had a 
median age at onset of 1.1 years. Several symptoms, including 
sleep disturbances/snoring, enlarged tongue, cognitive impair-
ment, and splenomegaly had a median age at onset of 1.2 years, 
whereas cardiac valve abnormalities were noted at a median age 
of 1.3 years. The symptoms that appeared latest in at least 25% 
of patients with Hurler syndrome were enlarged tonsils and 
joint contractures, with a median age at onset of 1.5 and 1.6 
years, respectively.
The symptoms reported in Hurler–Scheie patients are shown 
in Figure 2b. After hernias and coarse facial features, cognitive 
impairment was the earliest symptom observed, first occurring 
at a median age of 3.8 years. The median ages of onset for 
enlarged tongue, sleep disturbances/snoring, enlarged ton-
sils, joint contractures, and dysostosis multiplex were between 
4.0 and 4.2 years. Both corneal clouding and hepatomegaly 
had a median age at onset of 4.4 years, whereas splenomegaly 
and kyphosis/gibbus had a median age at onset of 4.6 years. 
Symptoms appearing later in patients with the Hurler–Scheie 
phenotype included cardiac valve abnormalities, hip dysplasia, 
and carpal tunnel syndrome, with median ages at onset of 5.7, 
6.2, and 7.4 years, respectively.
Symptoms reported in at least 25% of patients with Scheie 
phenotype are shown in Figure 2c. After hernias, the earliest 
symptoms within this phenotype were joint contractures and 
dysostosis multiplex, with median ages at onset of 7.6 and 8.0 
years, respectively. Hip dysplasia was first reported at a median 
age of 8.4 years. Both sleep disturbances/snoring and coarse 
facial features had a median age at onset of 8.7 years, and hepa-
tomegaly was observed at a median age of 9.4 years. Symptoms 
appearing later included corneal clouding at 10.5 years, spleno-
megaly at 11.0 years, cardiac valve abnormalities at 11.7 years, 
and carpal tunnel syndrome at 12.5 years.
DISCUSSION
MPS I is a rare panethnic genetic disorder characterized by a 
spectrum of disease with variable age of onset, progression, 
and organ involvement. If left untreated, patients with the most 
severe phenotype experience progressive deterioration of the 
musculoskeletal, cardiorespiratory, and central nervous sys-
tems and, typically, die before the age of 10 years.1 Although 
patients with the least severe phenotype usually have normal 
Figure 2 Prevalence and age of onset of signs and symptoms in patients with MPS I by phenotype. (a) Hurler, (b) Hurler–Scheie, and (c) Scheie. 
Percentages of symptom frequency are shown on the left axis. Only symptoms reported during the natural history period in at least 25% of patients with 
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cognitive functioning and survive into adulthood, more than 
50% may be affected by cardiac valve abnormalities, joint con-
tractures, corneal clouding, hernias, and hepatomegaly.15 The 
availability of improved disease-specific treatments, including 
HSCT and ERT, allows patients affected with MPS I to obtain 
substantial clinical benefit for many disease manifestations, 
including hepatosplenomegaly, upper airway obstruction 
(including sleep apnea), cardiac symptoms, and coarse facial 
features.3 Importantly, the chances of success from these treat-
ments is improved when initiated prior to the onset of irrevers-
ible organ damage.
Due to the rarity of the disease as well as the variability of 
clinical manifestations, MPS I poses challenges for diagnosis. 
The MPS I Registry provides the largest global data set for eval-
uating the natural history, clinical presentation, and potential 
treatment response of patients with MPS I.
The phenotypic distribution in the Registry data set, with 
most patients (60.9%) in the most severe phenotypic cate-
gory, Hurler, and the remaining more attenuated phenotypes, 
Hurler–Scheie (23%) and Scheie (12.9%), is consistent with 
existing data, suggesting that ~50–80% of patients have severe 
MPS I.4 However, the observed rates of the various phenotypes 
within the Registry may have been impacted by selection bias; 
e.g., more attenuated phenotypes could be underrepresented 
due to preferential identification and enrollment of patients 
with more severe clinical presentations. In an effort to mini-
mize selection bias, the Registry accepts all patients with a diag-
nosis of MPS I, regardless of treatment status.12
Regional differences in phenotypic distribution were also 
noted. North America and Europe had higher proportions of 
patients with the Hurler phenotype than did Latin America or 
the Asia Pacific region. These regional differences could be due 
to differences in the “genetic landscape” in different geographic 
regions or may be the result of regional differences in identifica-
tion and enrollment of MPS I patients in this voluntary Registry. 
Some evidence exists for regional genetic differences, in that 
certain severe mutations (common nonsense mutations) iden-
tified in North America and Europe have not been observed 
in the Asia Pacific region.2 The profile of MPS I mutations in 
Brazil also differs from that found in other regions.16 Based 
on the similarities in median ages of symptom onset, diagno-
sis, and treatment initiation, the present study suggests that a 
substantial proportion of patients in Latin America whose phe-
notypes were classified as undetermined/missing could have 
Hurler syndrome.
Early symptom recognition and diagnosis are essential to 
achieve the best long-term prognosis in patients with MPS 
I. It is of paramount importance that not only pediatricians, 
but other specialists as well, are familiar with the clinical 
manifestations and consider an MPS diagnosis, especially 
when symptoms are present in combination with each other. 
Hernias were the earliest presenting symptoms in all three 
phenotypes. Therefore, the presence of inguinal or umbilical 
hernias in young children should raise suspicion of MPS I. 
Likewise, coarse facial features, which are early manifestations 
and the most prevalent symptom in patients with Hurler and 
Hurler–Scheie phenotypes, should be considered as an early 
sign of a potential MPS I diagnosis. Corneal clouding is also 
a highly prevalent and relatively early manifestation of MPS I 
across the phenotypes.
Our findings indicate significant delays in diagnosis and 
treatment, particularly in patients with attenuated pheno-
types. Regional differences were evident as well, with attenu-
ated patients in Asia Pacific receiving treatment 18–22 years 
following the onset of symptoms—a 10- to 12-year delay 
compared with the 6–12 years between onset of symptoms 
and treatment in the overall Registry population. This delay 
may be due, in part, to a lack of access to ERT in some 
countries.
The data presented here confirm findings from a previous 
analysis of Registry data published in 2007, shortly after the 
Registry was established.12 The current analyses are based on 
a much larger set of patients (987 vs. 302), provide global and 
regional breakdowns of the data, and include data from the nat-
ural history period only. Regardless, and not surprisingly, there 
are similarities between the two reports in the age at symptom 
onset, age at diagnosis, and the rates of prevalence of common 
MPS I symptoms. However, the current report, based on data 
from a larger number of patients, provides a more detailed and 
refined analysis of the earlier findings.
When interpreting results of data analyses from the MPS I 
Registry, certain limitations common to observational regis-
tries should be considered.17,18 As with any voluntary registry, 
incomplete or missing data may affect the results, though a 
recent analysis of the MPS I Registry using source document 
verification revealed an overall source-to-database error rate of 
<4%, with no systematic errors.19 It is also possible that assess-
ment and data collection methods at the participating sites 
around the world may not be sufficiently standardized and/or 
that Registry enrollment biases, perhaps based on regional dis-
ease classification, symptom severity, and symptom reporting 
practices, affected the results. For example, patients who did 
not have a particular symptom may not have had any infor-
mation reported for that symptom (i.e., rather than indicat-
ing that a patient did not have a symptom, the investigator did 
not provide information about that symptom). This possibility 
led us to calculate symptom prevalence rates as the number 
of patients with a particular reported symptom divided by the 
total number of patients in each region and/or phenotype. As 
a consequence, the true symptom prevalence rates are at least 
what we have calculated, and may be higher. In this study, a 
slightly higher than expected number of patients with attenu-
ated MPS I had cognitive impairment (31.3% of Hurler–Scheie 
and 9.4% of Scheie patients). This likely reflects the fact that 
MPS I presents as a disease continuum, making phenotypic 
classification of MPS I somewhat subjective. Thus, it is pos-
sible that some Hurler and Hurler–Scheie patients may have 
been misclassified as Hurler–Scheie and Scheie phenotypes, 
respectively. Although the aforementioned potential limita-
tions are not insignificant, the data compiled in the MPS I 
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Registry are clearly valuable for drawing inferences and gen-
erating hypotheses.
Conclusions
The MPS I Registry is the largest global database of infor-
mation from MPS I patients and provides a useful tool for 
expanding knowledge about disease presentation, clini-
cal status, and treatment outcomes. Greater understand-
ing of the symptomatology of the disease can lead to earlier 
diagnosis and initiation of treatment, which may in turn 
lead to better patient outcomes. Each of the three MPS I 
phenotypes, Hurler, Hurler–Scheie, and Scheie, is associated 
with a characteristic constellation of symptoms and disease 
course. This analysis of data from almost 1,000 patients facili-
tates definition of the natural history of MPS I across the phe-
notypic spectrum, which will hopefully increase awareness of 
the disease and improve early diagnosis. In addition, results 
from this investigation will be important in establishing 
benchmarks for future analyses of treatment interventions.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper 
at http://www.nature.com/gim
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